MiR-221作为喉癌患者术前和术后的血浆生物标志物。
MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients.
作者信息
Yilmaz Seda Salman, Guzel Esra, Karatas Omer Faruk, Yilmaz Mehmet, Creighton Chad J, Ozen Mustafa
机构信息
Department of Medical Genetics, Istanbul University Cerrahpasa Medical School.
Biruni University.
出版信息
Laryngoscope. 2015 Dec;125(12):E377-81. doi: 10.1002/lary.25332. Epub 2015 May 6.
OBJECTIVE
In order to identify a plasma microRNA (miRNA) signature of larynx cancer (LCa), we examined miRNAs profile of plasma samples obtained from 30 LCa patients (preoperative and postoperative serum samples) and 30 healthy controls.
STUDY DESIGN
Basic science research study.
METHODS
MicroRNA profiling of eight plasma samples (four from preoperative, four from control individuals) were performed using miRNA microarray. Two of the significantly deregulated miRNAs were selected for further confirmation in the remaining samples using quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
RESULTS
Microarray profiling and qRT-PCR analysis showed that miR-221 was upregulated in LCa plasma samples. Further qRT-PCR analysis demonstrated that miR-221 was at normal levels in postoperative plasma samples.
CONCLUSIONS
Plasma miR-221 may have a potential as a novel diagnostic/prognostic marker and might be considered as a therapeutic target in LCa.
LEVEL OF EVIDENCE
N/A.
目的
为了鉴定喉癌（LCa）的血浆微小RNA（miRNA）特征，我们检测了30例LCa患者（术前和术后血清样本）及30名健康对照者的血浆样本中的miRNA谱。
研究设计
基础科学研究。
方法
使用miRNA微阵列对八个血浆样本（四个来自术前，四个来自对照个体）进行miRNA谱分析。选择两个显著失调的miRNA，使用定量逆转录聚合酶链反应（qRT-PCR）在其余样本中进行进一步验证。
结果
微阵列分析和qRT-PCR分析表明，miR-221在LCa血浆样本中上调。进一步的qRT-PCR分析表明，miR-221在术后血浆样本中处于正常水平。
结论
血浆miR-221可能具有作为新型诊断/预后标志物的潜力，并且可能被视为LCa的治疗靶点。
证据水平
无。
Zotero 插件